I don't see how that works in practice. Even if Hikma were acquired or exited, there are still multiple other generics already selling. Buying Hikma doesn't unwind generic entry or restore exclusivity. Also, Novartis buying both Amarin and a major generic manufacturer just to clean up one product seems like massive overkill and would raise serious antitrust issues. Settlement or licensing resolves litigation far more efficiently.
Market Data 
Markets 
AI
